Thus, we implicate the protein-protein interactions of PLK1 and PLK4 in the maintenance of mutant KRAS-expressing cancers, and illustrate the use of compounds that block these interactions in single-agent or combination therapies. This evidence concerns the gene PLK1 and cancer.